SCHEMBL9983649

SCHEMBL9983649

CCOc1ccc(N2CCC(CNC)CC2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.51
ALDH1A1 P00352 4/20 0.51
KMT2A Q03164 3/20 0.49
ALOX15 P16050 2/20 0.49
MEN1 O00255 2/20 0.49
GAA P10253 2/20 0.49
KDM4E B2RXH2 1/20 0.49
APP P05067 1/20 0.49
ALOX12 P18054 1/20 0.49
MAPK1 P28482 1/20 0.49
SNCA P37840 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
NPC1 O15118 2/20 0.48
TP53 P04637 1/20 0.48
RAB9A P51151 1/20 0.48
BACE1 P56817 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
HSD17B10 Q99714 1/20 0.46
ACACB O00763 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9983647 0.83 ALDH1A1 (0.50) MAPTALDH1A1KMT2AALOX15MEN1
SCHEMBL12916521 0.80 MEN1 (0.51) MAPTKMT2AMEN1GAAL3MBTL1
SCHEMBL27363642 0.79 MAPT (0.65) MAPTALDH1A1KMT2AALOX15MEN1
SCHEMBL10154050 0.78 ADRA1D (0.51) ALOX15MAPK1L3MBTL1NPC1HSD17B10
SCHEMBL9984934 0.78 CKS1B (0.56) MAPTALDH1A1KMT2AALOX15MEN1
SCHEMBL9983648 0.76 MAPT (0.51) MAPTALDH1A1KMT2AALOX15MEN1
SCHEMBL4724848 0.76 MAPT (0.69) MAPTALDH1A1KMT2AALOX15MEN1
SCHEMBL785012 0.75 ROCK2 (0.54) L3MBTL1LRRK2
SCHEMBL24654387 0.75 MAPT (0.49) MAPTALDH1A1KMT2AALOX15MEN1
SCHEMBL946519 0.75 HRH3 (0.52) MAPTALDH1A1ALOX15GAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096524-B2 Anthelmintic agents and their use INTERVET INTERNATIONAL B.V. (NL) 2015-08-04 US disclosed
US-9096524-B2 Anthelmintic agents and their use INTERVET INTERNATIONAL B.V. (NL) 2015-08-04 US disclosed
US-9096524-B2 Anthelmintic agents and their use INTERVET INTERNATIONAL B.V. (NL) 2015-08-04 US disclosed
EP-2408742-B1 ANTHELMINTIC AGENTS AND THEIR USE INTERVET INT BV (NL) 2014-09-03 EP disclosed
EP-2408742-B1 ANTHELMINTIC AGENTS AND THEIR USE INTERVET INT BV (NL) 2014-09-03 EP disclosed
US-20110319393-A1 ANTHELMINTIC AGENTS AND THEIR USE INTERVET INTERNATIONAL B.V. (NL) 2011-12-29 US disclosed
US-20110319393-A1 ANTHELMINTIC AGENTS AND THEIR USE INTERVET INTERNATIONAL B.V. (NL) 2011-12-29 US disclosed
US-20110319393-A1 ANTHELMINTIC AGENTS AND THEIR USE INTERVET INTERNATIONAL B.V. (NL) 2011-12-29 US disclosed
WO-2010115688-A1 ANTHELMINTIC AGENTS AND THEIR USE INTERVET INTERNATIONAL B.V. (NL) 2010-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319393-A1 ANTHELMINTIC AGENTS AND THEIR USE ACHE, ABCB11, MPO MAPT 1648/4885ALDH1A1 864/4885KMT2A 1866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.